Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels

To investigate the therapeutic effect and safety of celecoxib adding on doxazosin and the potential predictive value of the absence of prostate cancer in the treatment of patients with LUTS/BPH and an elevated serum PSA level. Patients who meet all eligible requirements for entry into the study will be randomized into one of the two treatment groups for 3 months in 2:1 ratio as shown below: 1. Doxazosin 4 mg daily plus celecoxib 200 mg every day (QD) 2. Doxazosin 4mg every day (QD)

Sex

Male

Minimum age

40 Years

Inclusion Criteria:

* Male adults aged ≥ 40 years with LUTS/BPH, IPSS ≥ 8
* Free of active urinary tract infection
* Free of neurogenic voiding dysfunction
* No history of previous prostate biopsy within 6 months
* No treatment of BPH by alpha-blocker or 5-alpha-reductase inhibitor within 6 months
* Patient or his legally acceptable representative has signed the written informed consent form

Exclusion Criteria:

* Patients with severe cardiopulmonary disease and such as congestive heart failure, arrhythmia, poorly controlled hypertension, not able to receive regular follow-up
* Patients with acute r chronic urinary retention and urodynamically proven detrusor underactivity
* Patients with postvoid residual \> 250 mL
* Patients have laboratory abnormalities at screening including:

  1. Aspartate aminotransferase (AST) \> 3 x upper limit of normal range
  2. Alanine aminotransferase (ALT) \> 3 x upper limit of normal range
  3. Patients have abnormal serum creatinine level \> 2 x upper limit of normal range
* Patients with any other serious disease or condition considered by the investigator not suitable for entry into the trial
* Patients participated investigational drug trial within 1 month before entering this study

• BACKGROUNDLiu HT, Kuo HC. Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment. Urology. 2008 Jul;72(1):104-8; discussion 108. doi: 10.1016/j.urology.2008.01.069. Epub 2008 Apr 8. PMID 18400272
• BACKGROUNDSt Sauver JL, Sarma AV, Jacobson DJ, McGree ME, Lieber MM, Girman CJ, Nehra A, Jacobsen SJ. Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort. Am J Epidemiol. 2009 Jun 1;169(11):1281-90. doi: 10.1093/aje/kwp085. Epub 2009 Apr 24. PMID 19395697
• BACKGROUNDAndersson KE. LUTS treatment: future treatment options. Neurourol Urodyn. 2007 Oct;26(6 Suppl):934-47. doi: 10.1002/nau.20500. PMID 17696154
• BACKGROUNDKuo HC. Videourodynamic analysis of pathophysiology of men with both storage and voiding lower urinary tract symptoms. Urology. 2007 Aug;70(2):272-6. doi: 10.1016/j.urology.2007.03.063. PMID 17826488
• BACKGROUNDDi Silverio F, Gentile V, De Matteis A, Mariotti G, Giuseppe V, Luigi PA, Sciarra A. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol. 2003 Feb;43(2):164-75. doi: 10.1016/s0302-2838(02)00548-1. PMID 12565775
• BACKGROUNDSciarra A, Mariotti G, Salciccia S, Autran Gomez A, Monti S, Toscano V, Di Silverio F. Prostate growth and inflammation. J Steroid Biochem Mol Biol. 2008 Feb;108(3-5):254-60. doi: 10.1016/j.jsbmb.2007.09.013. Epub 2007 Sep 7. PMID 17935971
• BACKGROUNDSciarra A, Di Silverio F, Salciccia S, Autran Gomez AM, Gentilucci A, Gentile V. Inflammation and chronic prostatic diseases: evidence for a link? Eur Urol. 2007 Oct;52(4):964-72. doi: 10.1016/j.eururo.2007.06.038. Epub 2007 Jul 2.